NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-14)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

NeuroBo Pharmaceuticals (NRBO US)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-14)

Current Report (Form 8-K | Period ending 2024-08-13)

Current Report (Form 8-K | Period ending 2024-08-06)

Current Report (Form 8-K | Period ending 2024-07-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)